Clinical implications of pleural effusions in ovarian cancer

José M. Porcel, John P. Diaz, Dennis S. Chi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The pleural cavity constitutes the most frequent extra-abdominal metastatic site in ovarian carcinoma (OC). In patients with OC and pleural effusions, a positive fluid cytology is required for a stage IV diagnosis. Unfortunately, about 30% of malignant pleural effusions exhibit false-negative cytological pleural fluid results. In those circumstances, exploratory video-assisted thoracoscopic surgery (VATS) serves as a diagnostic, staging and even therapeutic modality. Maximal (no visible disease) or, at least, optimal (no residual implant greater than 1 cm) cytoreduction should be the primary surgical goal in stage IV OC patients. This is due to residual tumour after cytoreductive surgery being one of the most important factors impacting on survival. Although malignant pleural effusions do not preclude abdominal surgical debulking, excision of gross pleural nodules may be necessary to achieve optimal cytoreduction. VATS quantifies pleural tumour burden and allows for intrathoracic cytoreduction or, if the latter is not feasible, ensures that abdominal surgery is not unnecessarily performed on women in whom gross tumour would still remain in the pleural space afterwards. Taxane-platinum neoadjuvant chemotherapy should be offered to this group. Patients with tumour extension into the pleural space have a median overall survival of 2 years.

Original languageEnglish
Pages (from-to)1060-1067
Number of pages8
JournalRespirology
Volume17
Issue number7
DOIs
StatePublished - Oct 1 2012

Fingerprint

Pleural Effusion
Ovarian Neoplasms
Malignant Pleural Effusion
Video-Assisted Thoracic Surgery
Carcinoma
Pleural Cavity
Survival
Residual Neoplasm
Platinum
Tumor Burden
Cell Biology
Neoplasms
Drug Therapy
Therapeutics

Keywords

  • malignant pleural effusion
  • ovarian cancer
  • pleurodesis
  • thoracoscopy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Clinical implications of pleural effusions in ovarian cancer. / Porcel, José M.; Diaz, John P.; Chi, Dennis S.

In: Respirology, Vol. 17, No. 7, 01.10.2012, p. 1060-1067.

Research output: Contribution to journalArticle

Porcel, José M. ; Diaz, John P. ; Chi, Dennis S. / Clinical implications of pleural effusions in ovarian cancer. In: Respirology. 2012 ; Vol. 17, No. 7. pp. 1060-1067.
@article{027f87dbdbe64ca2aa7a3b2decce4ecd,
title = "Clinical implications of pleural effusions in ovarian cancer",
abstract = "The pleural cavity constitutes the most frequent extra-abdominal metastatic site in ovarian carcinoma (OC). In patients with OC and pleural effusions, a positive fluid cytology is required for a stage IV diagnosis. Unfortunately, about 30{\%} of malignant pleural effusions exhibit false-negative cytological pleural fluid results. In those circumstances, exploratory video-assisted thoracoscopic surgery (VATS) serves as a diagnostic, staging and even therapeutic modality. Maximal (no visible disease) or, at least, optimal (no residual implant greater than 1 cm) cytoreduction should be the primary surgical goal in stage IV OC patients. This is due to residual tumour after cytoreductive surgery being one of the most important factors impacting on survival. Although malignant pleural effusions do not preclude abdominal surgical debulking, excision of gross pleural nodules may be necessary to achieve optimal cytoreduction. VATS quantifies pleural tumour burden and allows for intrathoracic cytoreduction or, if the latter is not feasible, ensures that abdominal surgery is not unnecessarily performed on women in whom gross tumour would still remain in the pleural space afterwards. Taxane-platinum neoadjuvant chemotherapy should be offered to this group. Patients with tumour extension into the pleural space have a median overall survival of 2 years.",
keywords = "malignant pleural effusion, ovarian cancer, pleurodesis, thoracoscopy",
author = "Porcel, {Jos{\'e} M.} and Diaz, {John P.} and Chi, {Dennis S.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1111/j.1440-1843.2012.02177.x",
language = "English",
volume = "17",
pages = "1060--1067",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Clinical implications of pleural effusions in ovarian cancer

AU - Porcel, José M.

AU - Diaz, John P.

AU - Chi, Dennis S.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - The pleural cavity constitutes the most frequent extra-abdominal metastatic site in ovarian carcinoma (OC). In patients with OC and pleural effusions, a positive fluid cytology is required for a stage IV diagnosis. Unfortunately, about 30% of malignant pleural effusions exhibit false-negative cytological pleural fluid results. In those circumstances, exploratory video-assisted thoracoscopic surgery (VATS) serves as a diagnostic, staging and even therapeutic modality. Maximal (no visible disease) or, at least, optimal (no residual implant greater than 1 cm) cytoreduction should be the primary surgical goal in stage IV OC patients. This is due to residual tumour after cytoreductive surgery being one of the most important factors impacting on survival. Although malignant pleural effusions do not preclude abdominal surgical debulking, excision of gross pleural nodules may be necessary to achieve optimal cytoreduction. VATS quantifies pleural tumour burden and allows for intrathoracic cytoreduction or, if the latter is not feasible, ensures that abdominal surgery is not unnecessarily performed on women in whom gross tumour would still remain in the pleural space afterwards. Taxane-platinum neoadjuvant chemotherapy should be offered to this group. Patients with tumour extension into the pleural space have a median overall survival of 2 years.

AB - The pleural cavity constitutes the most frequent extra-abdominal metastatic site in ovarian carcinoma (OC). In patients with OC and pleural effusions, a positive fluid cytology is required for a stage IV diagnosis. Unfortunately, about 30% of malignant pleural effusions exhibit false-negative cytological pleural fluid results. In those circumstances, exploratory video-assisted thoracoscopic surgery (VATS) serves as a diagnostic, staging and even therapeutic modality. Maximal (no visible disease) or, at least, optimal (no residual implant greater than 1 cm) cytoreduction should be the primary surgical goal in stage IV OC patients. This is due to residual tumour after cytoreductive surgery being one of the most important factors impacting on survival. Although malignant pleural effusions do not preclude abdominal surgical debulking, excision of gross pleural nodules may be necessary to achieve optimal cytoreduction. VATS quantifies pleural tumour burden and allows for intrathoracic cytoreduction or, if the latter is not feasible, ensures that abdominal surgery is not unnecessarily performed on women in whom gross tumour would still remain in the pleural space afterwards. Taxane-platinum neoadjuvant chemotherapy should be offered to this group. Patients with tumour extension into the pleural space have a median overall survival of 2 years.

KW - malignant pleural effusion

KW - ovarian cancer

KW - pleurodesis

KW - thoracoscopy

UR - http://www.scopus.com/inward/record.url?scp=84866667034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866667034&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2012.02177.x

DO - 10.1111/j.1440-1843.2012.02177.x

M3 - Article

C2 - 22458298

AN - SCOPUS:84866667034

VL - 17

SP - 1060

EP - 1067

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 7

ER -